EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects

EDP‐297 is a farnesoid X receptor agonist under development for treating nonalcoholic steatohepatitis. The pharmacokinetic (PK), pharmacodynamic (PD), food effect, and safety were evaluated in a single ascending dose (SAD) and multiple ascending dose (MAD) phase I study. Healthy subjects received si...

Descripción completa

Detalles Bibliográficos
Autores principales: Marotta, Christine, Ahmad, Alaa, Luo, Ed, Oosterhaven, Jart, van Marle, Sjoerd, Adda, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926082/
https://www.ncbi.nlm.nih.gov/pubmed/36369848
http://dx.doi.org/10.1111/cts.13453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926082/
https://www.ncbi.nlm.nih.gov/pubmed/36369848
http://dx.doi.org/10.1111/cts.13453

Ejemplares similares